Parameters N NFκB
n(%)
p HIF-1α
n(%)
p P-selectin
n(%)
P
  Total number 67 48(71.6)   49(73.1)   18(23.9)  
Age
<68 years
≥68 years

26
41

17 (65.4)
31 (75.6)
0.41
18 (69.2)
31 (75.6)
0.58
6 (23.1)
12 (26.3)
0.78
Sex
Male
Female

38
29

31(81.6)
17(58.6)
0.056
27(71.0)
22(75.9)
0.78
7(18.4)
11(37.9)
0.17
Tumour site
Colon (R+L+T)
sigmoid
Rectum

34
24
9

27(79.4)
17(70.8)
4(44.4)
0.11
24(70.6)
20(83.3)
5(55.5)
0.24
8(23.5)
8(33.3)
2(22.2)
0.67
Tumour grade
Well D
Moderately D
Poorly D

26
34
4

20(76.9)
23(67.6)
3(75.0)
0.57
19(73.1)
27(79.4)
1(25.0)
0.066
8(30.8)
8(23.5)
1(25.0)
0.81
pTNM Stage
I
II
III+IV

6
32
29

2(33.3)
25(78.1)
21(72.4)
0.082
5(83.4)
25(78.1)
19(65.5)
0.45
4(66.7)
10(31.2)
4(13.8)
0.022
pT stage
T1+T2
T3
T4

7
45
15

2(28.6)
33(73.3)
13(86.7)
0.017
5(71.4)
34(75.5)
10(66.7)
0.79
4(57.1)
11(24.4)
3(20.0)
0.24
pN stage
Node negative
Node positive

38
29

27(71.0)
21(72.4)
1.0
30(78.9)
19(65.5)
0.27
14(36.8)
4(13.8)

14(36.8)
4(13.8)
Expression was assessed by immunohistochemistry. Data are given as positive cases and percentage (in brackets) based on N. Association between markers and clinicopathological data was obtained using the Chi-square test or Fisher’s exact test. D: differentiated; in bold significant p values.
Table 2: Association between marker positive expression and clinicopathology